The current stock price of BLDE is 4.73 USD. In the past month the price increased by 18.55%. In the past year, price increased by 51.12%.
ChartMill assigns a technical rating of 10 / 10 to BLDE. When comparing the yearly performance of all stocks, BLDE is one of the better performing stocks in the market, outperforming 89.75% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to BLDE. While BLDE has a great health rating, there are worries on its profitability.
Over the last trailing twelve months BLDE reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 62.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.36% | ||
| ROE | -8.51% | ||
| Debt/Equity | 0 |
11 analysts have analysed BLDE and the average price target is 7.91 USD. This implies a price increase of 67.12% is expected in the next year compared to the current price of 4.73.
For the next year, analysts expect an EPS growth of 64.16% and a revenue growth 7.5% for BLDE
Blade Air Mobility, Inc. engages in providing air transportation alternatives through a technology-powered and global air mobility platform. The company is headquartered in New York City, New York and currently employs 310 full-time employees. The company went IPO on 2019-09-17. The firm transports human organs for transplant, and for passengers, with helicopter and fixed wing services primarily in the Northeast United States and Southern Europe. The company operates in three key product lines across its Passenger and Medical segments. Its Passenger segment includes Short Distance and Jet and Other. Short Distance business consists of helicopter and amphibious seaplane flights in the United States and Europe. Jet and Other business consists of non-medical jet charter and brand partners for exposure to Blade fliers and certain ground transportation services. Its Medical segment includes MediMobility Organ Transport, which consists of the transportation of human organs for transplant and/or the medical teams supporting these services. The company also offers additional services including donor logistics coordination and support for evaluating potential donor organs.
BLADE AIR MOBILITY INC
55 Hudson Yards, 14th Floor
New York City NEW YORK 80206 US
CEO: Eric Affeldt
Employees: 310
Phone: 12129671009
Blade Air Mobility, Inc. engages in providing air transportation alternatives through a technology-powered and global air mobility platform. The company is headquartered in New York City, New York and currently employs 310 full-time employees. The company went IPO on 2019-09-17. The firm transports human organs for transplant, and for passengers, with helicopter and fixed wing services primarily in the Northeast United States and Southern Europe. The company operates in three key product lines across its Passenger and Medical segments. Its Passenger segment includes Short Distance and Jet and Other. Short Distance business consists of helicopter and amphibious seaplane flights in the United States and Europe. Jet and Other business consists of non-medical jet charter and brand partners for exposure to Blade fliers and certain ground transportation services. Its Medical segment includes MediMobility Organ Transport, which consists of the transportation of human organs for transplant and/or the medical teams supporting these services. The company also offers additional services including donor logistics coordination and support for evaluating potential donor organs.
The current stock price of BLDE is 4.73 USD. The price increased by 3.28% in the last trading session.
BLDE does not pay a dividend.
BLDE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BLDE.
BLADE AIR MOBILITY INC (BLDE) will report earnings on 2025-11-10.